HR negative

Conclusion P53 expression is associated with aggressive clinicopathological features like large tumour size, high Ki-67 index and the HER2-enriched subtype, suggesting its role in tumour progression and aggressiveness. Further, large multicentric studies with survival analysis are needed to confirm its clinical validity.

Our findings demonstrate that BRCA1 protein loss delineates a distinct aggressive tumor biology within high-risk breast cancers. We emphasize that BRCA1 IHC is a complementary biomarker and cannot supplant germline genetic testing for clinical decision-making regarding targeted therapies.

ER/PR expression in PASH is less frequent than previously reported by some studies. However, the frequency of fat necrosis and associated fibrocystic changes in PASH support a chronic, hormone-related process. Consistent CD34 positivity and absence of markers seen in histologic mimics aid in the diagnosis of PASH in challenging cases. PASH does not appear to impart increased cancer risk.

Up to 13% of patients with stage III HER2+ or TNBC received treatment for brain metastases within 5 years of diagnosis with early-stage breast cancer. These findings support prospective studies of risk-stratified screening for asymptomatic brain metastases in patients with early-stage breast cancer.

MRI-guided optimisation of neoadjuvant chemotherapy duration was associated with favourable 3-year event-free survival outcomes in patients with stage II-III HER2-positive breast cancer. This approach represents a novel strategy that reduces treatment burden, minimises toxicity, and preserves quality of life in a subset of patients with early HER2-positive breast cancer.

Furthermore, its diagnostic capability using exosomes derived from HER2+/HR- cells achieves a LOD of 1.2 × 103 particles/mL, demonstrating strong clinical applicability. The proposed aptamer-integrated electrochemical biosensing platform is a noninvasive and point-of-care approach for the early diagnosis of HER2+/HR- subtype, providing insights into molecularly targeted BC diagnostics.

P2/3, N=224, Recruiting, Fundacio De Recerca Clinic Barcelona-Institut DInvestigacions Biomediques August Pi I Sunyer

The patient was treated with neoadjuvant chemotherapy followed by unilateral mastectomy. This case illustrates the clinical utility of evaluating all foci in multifocal high-grade disease to ensure appropriate systemic therapy and highlights the challenges of interpreting germline variants in the absence of well-described genotype-phenotype associations.

Single-dye SLNB after NAT in patients initially diagnosed with cN1 breast cancer yielded a clinically acceptable FNR. When four or more SLNs were identified, an additional benefit was observed in patients who had a BMI <25 kg/m2 and negative estrogen receptor status.

P2, N=36, Not yet recruiting, Laura Huppert, MD, BA | Trial completion date: Mar 2029 --> Jun 2029 | Trial primary completion date: Mar 2029 --> Jun 2029

Molecular sub-types in endometrial cancer reflect distinct and reproducible phenotypes. However, classic histopathologic features remain the strongest predictors of nodal spread and SLN detection failure.

Because of this, early risk assessment and tailored imaging are crucial for timely diagnosis. This review defines high-risk factors for breast cancer, and the management of these individuals during pregnancy and lactation.